Mulige komplikationer kan ofte undgås ved at sikre, at patienterne: – ikke er overfølsomme over for humant normalt immunglobulin ved initialt at injicere lægemidlet langsomt (≤0, 3 ml/ kg legemsvægt/ time); – monitoreres omhyggeligt for eventuelle symptomer under hele infusionsperioden.
Potential complications can often be avoided by ensuring that patients: – are not sensitive to human normal immunoglobulin by initially infusing the product slowly (0.3 ml/kg bw/hr); – are carefully monitored for any symptoms throughout the infusion period.